Executive Change: Turn Therapeutics Inc. (NASDAQ: TTRX) Appoints Robert Redfield M.D. as Chief Scientific Officer

Westlake Village, CA – Turn Therapeutics Inc. has announced the appointment of Robert Redfield as Chief Scientific Officer. About Turn Therapeutics Inc.: Turn Therapeutics Inc. is a clinical-stage biotechnology company that develops first-in-class, targeted topical therapies designed to act directly within the skin at the site of disease. Based on its website, the company focuses on advancing localized, non-systemic treatments that prevent unnecessary immune activation, aiming to avoid systemic exposure and injections while still addressing inflammatory and infectious skin conditions. Turn Therapeutics core technology includes PermaFusion, a proprietary drug delivery platform, created by its founder and CEO Bradley Burnam after his experience with a hospital-acquired skin infection, and used to enhance drug performance in dermatology, wound care, and infectious disease applications. The company positions itself as mission-driven, emphasizing increased access to effective medicines for high-need populations and developing therapies that operate where disease occurs rather than affecting healthy tissue. Headquartered in Westlake Village, California, Turn Therapeutics highlights its role as an innovator in advanced wound care and skin disease treatment, supported by strategic industry partnerships and a growing pipeline built on its proprietary platforms.

For more information visit: https://turntherapeutics.com/

Turn Therapeutics Inc.
250 N Westlake Blvd Suite 210
Westlake Village, CA 91362
Phone: 818-564-4011
LinkedIn: https://www.linkedin.com/company/turn-therapeutics

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved